Nan You
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
- Hepatology 24
- Hepatocellular Carcinoma Treatment and Prognosis 16
- Liver physiology and pathology 7
-
- Cancer Genomics and Diagnostics 3
- Co-authors
- Kaishan Tao (12 shared papers)Kefeng Dou (10 shared papers)Lu Zheng (18 shared papers)Weihui Liu (11 shared papers)Desheng Wang (4 shared papers)Xiaobing Huang (11 shared papers)Ru Ji (5 shared papers)Weiwei Wang (6 shared papers)
- Journals
- PLoS ONE (4 papers)Radiology (3 papers)Cell Death and Disease (3 papers)Oncology Reports (2 papers)Cellular Oncology (2 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Nan You
68 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 107
- Hepatology 411
- Cancer Research 368
- Geriatrics and Gerontology 42
- Oncology 236
- Molecular Biology 572
Countries citing papers authored by Nan You
This map shows the geographic impact of Nan You's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan You with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan You more than expected).
Fields of papers citing papers by Nan You
This network shows the impact of papers produced by Nan You. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan You. The network helps show where Nan You may publish in the future.
Co-authors
The 25 scholars most cited alongside Nan You, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 74 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 204 | |
| 2 | 2013 | 147 | |
| 3 | 2012 | 110 | |
| 4 | 2017 | 94 | |
| 5 | 2013 | 89 | |
| 6 | 2016 | 77 | |
| 7 | 2013 | 65 | |
| 8 | Resveratrol transcriptionally regulates miRNA-18a-5p expression ameliorating diabetic nephropathy via increasing autophagy. | 2017 | 59 |
| 9 | 2010 | 57 | |
| 10 | 2020 | 47 | |
| 11 | 2017 | 42 | |
| 12 | 2014 | 39 | |
| 13 | 2012 | 34 | |
| 14 | 2018 | 28 | |
| 15 | 2023 | 27 | |
| 16 | 2012 | 26 | |
| 17 | 2020 | 25 | |
| 18 | 2020 | 25 | |
| 19 | 2011 | 25 | |
| 20 | 2017 | 21 |
About Nan You
Nan You is a scholar working on Hepatology, Cancer Research, Oncology, Surgery and Molecular Biology, having authored 74 papers that have together received 1.6k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Liver physiology and pathology (7 papers), Cancer Cells and Metastasis (5 papers), Pancreatic and Hepatic Oncology Research (5 papers), Helicobacter pylori-related gastroenterology studies (4 papers), Epigenetics and DNA Methylation (4 papers), Cancer Genomics and Diagnostics (3 papers) and Cancer Mechanisms and Therapy (3 papers). The work is most often cited by research in Hepatology (411 citations), Cancer Research (368 citations), Geriatrics and Gerontology (42 citations), Oncology (236 citations) and Molecular Biology (572 citations). Nan You has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Kaishan Tao, Kefeng Dou, Lu Zheng, Weihui Liu, Desheng Wang, Xiaobing Huang, Ru Ji, Weiwei Wang, Liang Zhou and Xiaolei Li. Their work appears in journals such as PLoS ONE, Radiology, Cell Death and Disease, Oncology Reports and Cellular Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.